Home / People / Dr. Jörn Witt

Dr. Jörn Witt, LL.M. (University of London)

Partner
Rechtsanwalt

CMS Hasche Sigle
Stadthausbrücke 1-3
20355 Hamburg
Germany
Languages English

Jörn Witt focuses on the life sciences industry and advises pharmaceutical companies, medical device manufacturers as well as companies in related regulated industries. He particularly concentrates on regulatory and reimbursement matters and also assists his clients with drafting and negotiating cooperation and development agreements for business development purposes. Jörn furthermore represents his clients in contentious cases and regularly advises on transactions in the life sciences sector.

Jörn’s practice covers licensing and pharmaceutical laws as well as drugs and medical devices advertising law. He also advises his clients on statutory health insurance law issues, in particular in the context of new forms of care. Across all industries, Jörn furthermore advises on intellectual property matters with a focus on trademark and competition law as well as anti-counterfeiting campaigns.

He joined CMS in 2006 and has been a partner since 2013.

more less

Education


  • Completed his PhD as a German Academic Scholarship Foundation scholar; topic: broadcasting law
  • 2006: Second state examination in law
  • Trainee lawyer in Hamburg
  • 2001 - 2004: Research assistant for Prof. Dr. Hubertus Gersdorf, University of Rostock
  • LL.M. at Queen Mary University of London as a German Academic Exchange Service scholar
  • 2000: First state examination in law
  • Law studies in Hamburg
more less

Publications


  • Unlautere Nachahmung eines Medizinproduktes – Femur-Teil, zugleich Anmerkung zum BGH-Urteil vom 15.4.2010 - I ZR 145/08; MPR 2011, 42
  • Internet-Aktivitäten öffentlich-rechtlicher Rundfunkanstalten, Duncker & Humblot 2007
more less

Feed

Show only
26/06/2020
Apotal Group sells on­line phar­macy’s mail-or­der busi­ness and dia­betes arm...
Stut­tgart – Com­pany founder Heinz-Peter Fichter and oth­er share­hold­ers have sold the mail-or­der busi­ness of on­line phar­macy Apotal and its dia­betes di­vi­sion to the lis­ted Zur Rose Group of Switzer­land...
20 April 2020
CMS Ex­pert Guide to can­nabis law and le­gis­la­tion
In re­cent years can­nabis trade and re­lated activ­ity has de­veloped in­to a growth busi­ness area. In the life sci­ences and health­care fields there have been in­creases in the num­bers of pa­tients hav­ing ac­cess...
23 November 2020
EU high court con­firms CBD is not a nar­cot­ic
In a long-awaited rul­ing, the European Court of Justice (ECJ) cla­ri­fied that the can­nabis act­ive in­gredi­ent Can­na­bi­d­i­ol (CBD) is not to be clas­si­fied as a nar­cot­ic. France sub­mits ques­tion on CBD in e-ci­gar­ettes...
15/08/2014
CMS ad­vises IBL In­ter­na­tion­al on its dis­pos­al to Tecan Group
Ham­burg - Tecan Group AG, a lead­ing glob­al pro­vider of labor­at­ory in­stru­ments and solu­tions, based in Männedorf, Switzer­land, ac­quires the IBL In­ter­na­tion­al-Group, whose main activ­it­ies are car­ried out...
01/08/2014
CMS ad­vises Almir­all on multi-bil­lion ac­quis­i­tion of res­pir­at­ory dis­ease...
Ham­burg – In­ter­na­tion­ally act­ive phar­ma­ceut­ic­al firm Almir­all S.A. (Bar­celona) has agreed with Lon­don-based As­traZeneca plc to trans­fer its drug plat­form for res­pir­at­ory dis­ease treat­ments. Once the...
01/08/2014
CMS ad­vises Almir­all on multi-bil­lion ac­quis­i­tion of res­pir­at­ory dis­ease...
Ham­burg – In­ter­na­tion­ally act­ive phar­ma­ceut­ic­al firm Almir­all S.A. (Bar­celona) has agreed with Lon­don-based As­traZeneca plc to trans­fer its drug plat­form for res­pir­at­ory dis­ease treat­ments. Once the...
08/01/2013
CMS Hasche Sigle 2013: Six new part­ners ap­poin­ted
Ber­lin – CMS Hasche Sigle has seen in the New Year by ap­point­ing six new part­ners. Man­aging Part­ner Dr Hubertus Kolster: "We would like to ex­tend a very warm wel­come to our new part­ners at the start...